Skip to main content
CRIS logo

CRIS · Curis Inc · Documents

Track CRIS — free
$0.43 -0.04 (-9.03%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$4.06M
Shares
9.51M
Volume · Nov 20 531.09K Avg daily vol (3M) 4.27M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $9.44M down 13.4% 10-K filed Mar 24, 2026 Quarterly report FY2026 Q3 Net loss $8.12M 10-Q filed Nov 13, 2026 Latest results Third-quarter loss widened with no revenue reported 8-K filed Nov 13, 2026 Earnings call Q3 2026 earnings call Held Nov 12, 2026
2026
Nov 13
Registration statement S-3
Registers 33,333,360 shares for resale

Curis, Inc. registered up to 33,333,360 common shares for resale by selling stockholders, including shares issuable upon exercise of October 2026 Pre-Funded Warrants and October 2026 Common Warrants sold in the October 2026 Private Placement.

Read from the first part of this long document
Source passage
This prospectus relates to the resale from time to time of up to 33,333,360 shares of common stock of Curis, Inc. by the selling stockholders listed on page 10, including their donees, pledgees, transferees or other successors-in-interest, consisting of (i) 2,574,517 shares of our common stock, par value $0.01, or the Common Stock, (ii) 14,092,163 shares of our Common Stock issuable upon the exercise of pre-funded warrants to purchase our Common Stock, or the October 2026 Pre-Funded Warrants, and (iii) 16,666,680 shares of our Common Stock issuable upon the exercise of warrants to purchase our Common Stock, or the October 2026 Common Warrants (or, in certain circumstances, pre-funded warrants). The shares of Common Stock, October 2026 Pre-Funded Warrants and October 2026 Common Warrants were sold to the selling stockholders in a private placement in October 2026, or the October 2026 Private Placement. Open the document at this passage
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Funding extends operations only into first quarter of 2027

Curis, Inc. says $5.0 million of cash plus approximately $7.5 million from the October 2026 Private Placement fund operations into the first quarter of 2027. Substantial going-concern doubt remains; Curis appealed Nasdaq’s November 2, 2026 delist determination.

Net loss $8.12M Diluted EPS -$1.94
Read from the MD&A section
4 source passages
our $5.0 million of existing cash and cash equivalents as of September 30, 2026, together with the net proceeds of approximately $7.5 million from the October 2026 Private Placement, should enable us to fund our existing operations into the first quarter of 2027. conditions and events that raise substantial doubt regarding our ability to continue as a going concern On November 2, 2026, we received a delist determination from Nasdaq for failure to comply with the minimum bid price requirement, which we have appealed. the term “Curis” refers to Curis, Inc. Open the document at this passage
Nov 13
Current report 8-K Events of Nov 12
Third-quarter loss widened with no revenue reported

Curis reported a third-quarter net loss of $8.1 million, no revenue, and $5.0 million cash as of September 30, 2026; it believes financing will fund operations into the first quarter of 2027, while 2 emavusertib studies continue enrolling.

Financial results
6 source passages
For the third quarter of 2026, Curis reported a net loss of $8.1 million or $1.94 per share on both a basic and diluted basis as compared to $7.7 million or $9.86 per share on both a basic and diluted basis, for the same period in 2025. There was no revenue reported for the quarter or the year ended September 30, 2026 due to the sale of Erivedge® royalties to Oberland in the fourth quarter of 2025. Curis's cash and cash equivalents totaled $5.0 million as of September 30, 2026, and the Company had approximately 4.1 million shares of common stock outstanding. The Company believes that the $5.0 million of existing cash and cash equivalents as of September 30, 2026, together with the net proceeds of approximately $7.5 million from the October 2026 Private Placement, should enable it to fund our existing operations into the first quarter of 2027. Curis is currently enrolling patients in 2 ongoing studies, the TakeAim CLL study (CA-4948-203, NCT07271667) and the TakeAim Lymphoma study in PCNSL (CA-4948-101, NCT03328078). Curis is a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor. Open the document at this passage
Nov 12
Earnings call
86% PCNSL response rate; NDA filing planned for 2028

Curis reported an 86% response rate in seven BTK-naive primary CNS lymphoma patients and responses in 10 of 39 salvage-line patients. Full enrollment is expected in 2027, followed by an NDA filing in 2028.

5 source passages
Thank you, and welcome to Curis' third quarter 2026 business update call. The updated data show an 86% response rate in BTKI-naive patients, with six of seven patients achieving a response. For large-line patients, those patients whose disease had progressed while taking a BTK inhibitor, the updated data show a 26% response rate with 10 of 39 patients responding when treated with the Mofusertib plus BTKI combination after they had already progressed on BTKI monotherapy. we expect to be fully enrolled in the study by the end of 2027. Filing it in 2028. Open the document at this passage
Nov 6
Current report 8-K Events of Nov 2
Nasdaq issues bid-price delist determination

Nasdaq notified Curis, Inc. on November 2, 2026 that common stock closed below the minimum $1.00 per share for 30 business days. A July 6, 2026 1-for-20 reverse stock split left the company ineligible for a compliance period.

Delisting notice or listing transfer
2 source passages
On November 2, 2026, Curis, Inc. (the “Company”) received a letter (the “Delist Determination Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). As the Company effected a 1-for-20 reverse stock split on July 6, 2026, the Company is not eligible for any compliance period specified in Rule 5810(c)(3)(A) Open the document at this passage
Nov 2
Proxy statement DEF 14A Meeting Nov 18, 2026
Stockholders to vote on 1-for-5 to 1-for-12 reverse split

Curis will ask stockholders at a virtual special meeting on November 18, 2026 to approve a reverse stock split ranging from 1-for-5 to 1-for-12, with the board determining the ratio.

Read from the first part of this long document
2 source passages
NOTICE IS HEREBY GIVEN that a Special Meeting of stockholders of Curis, Inc. (the “Special Meeting”) will be held exclusively online via the Internet as a virtual web conference at on November 18, 2026 at 11:00 a.m. Eastern Time for the purpose of considering and voting upon the following matters: To adopt and approve amendments to our Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our shares of common stock, by a ratio ranging from any whole number between 1-for-5 and 1-for-12, as determined by our Board of Directors (the “Board”) in its discretion, subject to the Board’s authority to abandon such amendments (the “Reverse Stock Split Proposal”); and Open the document at this passage
Oct 23
Proxy statement PRE 14A Meeting Nov 18, 2026
Reverse Split Between 1-for-5 and 1-for-12 Up for Vote

Curis seeks stockholder approval at a virtual special meeting on November 18, 2026 for a reverse stock split of its common stock at a ratio from any whole number between 1-for-5 and 1-for-12, set by the Board in its discretion and subject to its authority to abandon the amendments. Holders of record on October 26, 2026 will vote, and an adjournment vote is also sought.

Read from the first part of this long document
5 source passages
NOTICE IS HEREBY GIVEN that a Special Meeting of stockholders of Curis, Inc. (the “Special Meeting”) will be held exclusively online via the Internet as a virtual web conference at on November 18, 2026 at 11:00 a.m. Eastern Time to effect a reverse stock split of our shares of common stock, by a ratio ranging from any whole number between 1-for-5 and 1-for-12, as determined in its discretion, subject to the Board’s authority to abandon such amendments The board of directors has fixed the close of business on October 26, 2026 as the record date for the determination of stockholders entitled to notice of and to vote at the Special Meeting To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate Open the document at this passage
Oct 19
Current report 8-K Events of Oct 16
Private Placement Raises About $8.5 Million at $0.51 Per Share

Curis agreed to sell 16,666,680 shares of common stock, or pre-funded warrants, together with common warrants at an effective combined price of $0.51 per share. Gross proceeds are expected to be approximately $8.5 million before placement agent fees and offering expenses. The common warrants have a $0.60 exercise price and will terminate on April 19, 2032.

Entered into a material agreement, Unregistered sale of equity Read from the first part of this long document
5 source passages
for the purchase and sale of 16,666,680 shares (the “Shares”) of the Company’s common stock at an effective combined price of $0.51 per Share The gross proceeds from the Offering are expected to be approximately $8.5 million The Common Warrants have an exercise price of $0.60 per share will terminate on April 19, 2032 Open the document at this passage
Aug 14
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $0 Net loss $8.58M Diluted EPS -$4.02
Jun 5
Proxy statement DEF 14A Meeting Jun 25, 2026
Proxy statement AI summary on its way
May 22
Proxy statement PRE 14A Meeting Jun 25, 2026
Proxy statement AI summary on its way
May 13
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $0 Net loss $24.2M Diluted EPS -$1.25
Apr 21
Proxy statement DEF 14A Meeting May 19, 2026
Proxy statement AI summary on its way
Apr 10
Proxy statement PRE 14A Meeting May 19, 2026
Proxy statement AI summary on its way
Mar 24
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $9.44M ▼ 13.4% Net loss $7.58M Diluted EPS -$0.58
Feb 19
Proxy statement DEF 14A Meeting Mar 17, 2026
Proxy statement AI summary on its way
Feb 9
Proxy statement PRE 14A Meeting Mar 17, 2026
Proxy statement AI summary on its way
2025
Showing 1–50 of 175 documents
Key facts CIK 1108205 CUSIP 231269408 13F (30d) 52 filings 29 filers Visit website Investor relations